Arrowhead Pharmaceuticals, Inc.
ARWR
$82.63
-$2.48-2.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 171.02% | -86.41% | 10,461.32% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 171.02% | -86.41% | 10,461.32% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 171.02% | -86.41% | 10,461.32% | -- | -- |
| SG&A Expenses | 44.73% | 40.40% | 61.86% | 45.80% | 21.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.91% | 33.12% | 36.19% | 30.93% | 9.75% |
| Operating Income | -2.74% | -137.06% | 125.28% | 127.19% | 6.01% |
| Income Before Tax | 0.10% | -137.22% | 116.14% | 120.90% | -2.94% |
| Income Tax Expenses | 102.52% | -99.60% | -71.84% | 3,563.00% | -- |
| Earnings from Continuing Operations | -0.15% | -137.40% | 116.12% | 109.30% | -2.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -550.43% | 87.45% | 20.44% | -1,519.91% | 7.13% |
| Net Income | -10.86% | -135.83% | 117.80% | 86.07% | -2.60% |
| EBIT | -2.74% | -137.06% | 125.28% | 127.19% | 6.01% |
| EBITDA | -2.58% | -134.83% | 130.22% | 132.12% | 7.02% |
| EPS Basic | -7.51% | -133.55% | 116.21% | 87.44% | 8.35% |
| Normalized Basic EPS | -13.65% | -137.29% | 117.18% | 85.18% | 8.17% |
| EPS Diluted | -7.90% | -133.89% | 115.83% | 87.30% | 8.67% |
| Normalized Diluted EPS | -13.65% | -137.60% | 116.73% | 85.18% | 8.17% |
| Average Basic Shares Outstanding | 3.12% | 6.79% | 9.76% | 10.87% | 11.95% |
| Average Diluted Shares Outstanding | 3.12% | 5.90% | 12.70% | 10.87% | 11.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |